enGene Stock (NASDAQ:ENGN)


ForecastOwnershipFinancialsChart

Previous Close

$3.70

52W Range

$2.65 - $11.00

50D Avg

$3.65

200D Avg

$5.70

Market Cap

$186.02M

Avg Vol (3M)

$82.19K

Beta

-0.41

Div Yield

-

ENGN Company Profile


enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

56

IPO Date

Feb 01, 2022

Website

ENGN Performance


ENGN Financial Summary


Oct 22Oct 21Oct 20
Revenue---
Operating Income$-19.43M$-15.87M$-13.85M
Net Income$-24.46M$-23.44M$-15.07M
EBITDA$-19.45M$-15.70M$-12.90M
Basic EPS---
Diluted EPS---

Fiscal year ends in Oct 22 | Currency in USD